EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
+43.4%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$101M
AUM Growth
–
Cap. Flow
+$101M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
42.21%
Holding
52
New
52
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Dr. Reddy's Laboratories
RDY
|
$6.26M |
| 2 |
Eli Lilly
LLY
|
$5.65M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$5.54M |
| 4 |
Cigna
CI
|
$4.58M |
| 5 |
Celldex Therapeutics
CLDX
|
$4.41M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dr. Reddy's Laboratories
RDY
$11.8B
| $6.26M | 6.19% | +90,000 | New | +$6.26M |
|
|
2
Eli Lilly
LLY
$657B
| $5.65M | 5.59% | +9,700 | New | +$5.65M |
|
|
IMGN
3
DELISTED
Immunogen Inc
IMGN
| $5.54M | 5.48% | +186,900 | New | +$5.54M |
|
|
4
Cigna
CI
$80.3B
| $4.58M | 4.53% | +15,300 | New | +$4.58M |
|
|
5
Celldex Therapeutics
CLDX
$1.47B
| $4.41M | 4.36% | +111,300 | New | +$4.41M |
|
6
TG Therapeutics
TGTX
$4.65B
| $3.47M | 3.43% | +203,300 | New | +$3.47M |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $3.32M | 3.28% | +72,203 | New | +$3.32M |
|
|
ALPN
8
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $3.31M | 3.27% | +173,500 | New | +$3.31M |
|
9
DexCom
DXCM
$29.5B
| $3.08M | 3.05% | +24,828 | New | +$3.08M |
|
10
Madrigal Pharmaceuticals
MDGL
$9.76B
| $3.05M | 3.02% | +13,202 | New | +$3.05M |
|
11
Cytokinetics
CYTK
$4.23B
| $2.91M | 2.88% | +34,908 | New | +$2.91M |
|
|
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $2.78M | 2.75% | +73,158 | New | +$2.78M |
|
13
Structure Therapeutics
GPCR
$1.11B
| $2.78M | 2.74% | +68,100 | New | +$2.78M |
|
14
Rocket Pharmaceuticals
RCKT
$354M
| $2.75M | 2.72% | +91,800 | New | +$2.75M |
|
15
BridgeBio Pharma
BBIO
$9.89B
| $2.63M | 2.6% | +65,113 | New | +$2.63M |
|
|
ONC
16
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.31M | 2.28% | +12,800 | New | +$2.31M |
|
17
Legend Biotech
LEGN
$6.41B
| $2.28M | 2.25% | +37,900 | New | +$2.28M |
|
18
Penumbra
PEN
$10.6B
| $2.15M | 2.13% | +8,553 | New | +$2.15M |
|
19
Intuitive Surgical
ISRG
$170B
| $2.14M | 2.12% | +6,358 | New | +$2.14M |
|
20
Biogen
BIIB
$19.4B
| $2.12M | 2.1% | +8,200 | New | +$2.12M |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.03M | 2% | +28,300 | New | +$2.03M |
|
22
Biohaven
BHVN
$1.63B
| $1.95M | 1.92% | +45,467 | New | +$1.95M |
|
23
Insmed
INSM
$28.8B
| $1.91M | 1.88% | +61,500 | New | +$1.91M |
|
24
Lantheus
LNTH
$3.73B
| $1.8M | 1.78% | +29,100 | New | +$1.8M |
|
25
Catalyst Pharmaceutical
CPRX
$2.52B
| $1.77M | 1.75% | +105,500 | New | +$1.77M |
|